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Summary
Background: Acinetobacter baumannii is a troublesome and increasingly prob-
lematic healthcare-associated pathogen, especially in critical care unit. These or-
ganisms have a capacity for long-term survival in the hospital environment.
Aim: This study aimed to investigates the drug resistance patterns of Acinetobacter 
baumannii strains isolated from burn ICU (BICU). 
Method: The antibiotic susceptibility of 167 Acinetobacter baumannii isolates to 
imipenem, meropenem, gentamicin, ciprofloxacin, fusidic acid, amikacin, trime-
thoprim, cefepime, ceftazidime, ceftriaxone, cefotaxime, and amoxicillin-clavulanic 
acid was determined by disk agar diffusion test. 
Findings: A total 167 A. baumannii strains out of 4286 isolates were collected 
from various specimens during study period. The overall proportion of A. bauman-
nii isolates among all clinical isolates has increased slightly throughout the study 
from 3.5% to 4.2%. Carbapenem remained the antimicrobial most active antibiotic 
against A. baumannii isolates compared with other antibiotics. However, during the 
two years there was an increase in resistance from 50.6% to 71.3% to imipenem 
(P<0.01), and meropenem from 50.6% to 74.5% (P<0.01). ICU isolates exhib-
ited significantly higher level of resistance to imipenem (71.6%) and meropenem 
(73.4%) compared with non-ICU strains (42.6% and 44.6% respectively) (P<0.01).
Conclusion: Due to the high antimicrobial resistance in the ICU, we must focus 
on both a wiser use of antimicrobials and the prevention of infection. Continuous 
monitoring of antimicrobial susceptibility and strict adherence to infection preven-
tion guidelines are essential to eliminate major outbreaks in the future.
This article is available from: 
www.iajaa.org
Introduction
The emergence of resistance among gram-negative bacilli 
has been a growing problem during the past two decades. 
Among the problem microorganisms is Acinetobacter bau-
mannii, which emerged as one of the leading nosocomial 
pathogen, particularly in Intensive Care Units (ICUs), where 
several outbreaks have been described1-3. It is probably 
now accounts for 2-10% of Gram-negative bacterial infec-
tions in ICUs in Europe and the United States 4. The epi-
demic potential and the clinical severity of A. baumannii 
infections are primarily related to the ability to survive and 
spread within hospital environment and to develop resistance 
to a variety of antimicrobial agents, including broad-spec-
trum beta-lactams, fluoroquinolones, aminoglycosides, and 
carbapenems 5. Multidrug resistant A. baumannii (MDR) usu-
ally retained in vitro susceptibility to carbapenems 6. Imipe-
nem remain drugs of choice, but their efficacy can be com-
promised by the increasingly spread of resistance in several 
countries7-9. The aim of the study was to determine the drug 
resistance patterns of A. baumannii strains isolated from dif-
ferent units at burn and plastic surgery centre (BPSC) include 
burn ICU (BICU) patients during 2008-2009.
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Materials and Methods
Bacterial isolates
All A. baumannii clinical isolates identified in the BPSC (Trip-
oli, Libya) between 2008 and 2009 were selected. Initially 
conventional biochemical tests such as Gram stain, catalase, 
and oxidase tests were used 10. Then, Acinetobacter were 
characterized by phenotypic method by using API 20NE (bio-
Mérieux, France) for the identification at the species level. 
Hundred and sixty seven non-duplicate A. baumannii isolates 
recovered from routine cultures performed in the microbi-
ology laboratory from wounds and abscesses swabs, urine, 
blood culture, and others, derived from different wards (burn 
units, paediatric burn, plastic units) and BICU patients.
Antimicrobial susceptibility testing
Minimal inhibitory concentrations (MICs) were performed 
by agar dilution method and interpreted according to the 
Clinical and Laboratory Standards Institute (CLSI) guidelines 
against all isolates to determine the susceptibility of these 
isolates to such antibiotics 11. The antibiotic classes tested 
included: imipenem (10µg), meropenem (10µg), gentami-
cin (10µg), ciprofloxacin (5µg), fusidic acid (10µg), amikacin 
(30µg), trimethoprim (25µg), cefepime (30µg), ceftazidime 
(30 µg), ceftriaxone (30 µg), cefotaxime (10 µg), and amox-
icillin-clavulanic acid (30µg). Isolates showing intermediate 
level of susceptibility classified as resistant. MDR A. bauman-
nii defined as resistance to more than three classes of anti-
biotics. Escherichia coli ATCC 25922 and ATCC 35218 and 
Pseudomonas aeruginosa ATCC 27853 were used as quality 
controls in each susceptibility determination. All P values were 
two-tailed. P value <.05 was considered as significant. Open 
Epi software (Epi Info™ 7, Atlanta, GA, USA) was used for 
all statistical analyses.
Results 
During the study, 167 A. baumannii strains were isolated from 
patients, representing 73/2070 (3.5%) and 94/2216 (4.2%) 
of total samples received during the years 2008 and 2009 
respectively. There were 72 females (43.1%) and 95 males 
(56.9%). The median age was 35 (7months- 80years). The 
body sites and fluids from which the organism was recovered 
included urine (10 [6.0%] of the isolates), wound and abscess 
swabs (119 [71.2%]), bronchial lavage (16 [9.6%]) and blood 
(12 [7.2%]); the remaining isolates were recovered from other 
sites. A. baumannii ranked the fifth most frequently isolated 
microorganism isolated from patients in BICU, preceded by 
Staphylococci, Pseudomonas, Klebsiella and Candida.
The majority of strains were derived from BICU (n=113, 
67.7%) compared with wards (n=54, 32.3%). The antimicro-
bial resistance pattern is shown in Table 1, during two years 
of the study, all A. baumannii isolates were highly resistant 
to third generation cephalosporins (ceftazidime, ceftriaxone, 
Antimicrobial
agents
ICU (n=113) Non-ICU (n=54) Total 167
 n* %•  n* %•  n* %•
Amoxicillin/clavulanic acid 113 100 52 96.2 165 98.8
Cefotaxime 113 100 52 96.2 165 98.8
Ceftazidime 113 100 51 94.4 164 98.2
Ceftriaxone 113 100 52 96.2 165 98.8
Cefepime 108 95.5 46 85.2 154 92.2
Imipenem 81 71.6 23 42.6 104 62.3
Meropenem 83 73.4 24 44.4 107 64.1
Amikacin 109 96.4 47 87 156 93.4
Gentamicin 112 99.1 48 88.8 160 95.8
Ciprofloxacin 103 91.1 47 87 150 89.2
Trimethoprim 112 99.1 48 88.8 160 95.8
Fusidic acid 112 99.1 52 96.2 164 98.2
Table 1.  Distributions of antibiotic resistance for isolates of the A. baumannii complex.
*= number of isolate which are resistant to tested antibiotic.
•= total percent of isolates resistant to tested antibiotic
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and cefotaxime), and fusidic acid. High rates of resistance also 
demonstrated to cefepime (92.2%), amikacin (93.4%) and 
ciprofloxacin (89.2%). About 97.7% of the isolates defined 
as MDR. Of 167 Acinetobacter  isolates, 62.3% and 64.1% 
were resistant to imipenem and meropenem, respectively. 
However, there was significant increase in the proportion of 
resistance to imipenem (from 37/73 [50.6%] in 2008 to 67/94 
[71.3%] in 2009) (P<0.01), and to meropenem (from 37/73 
[50.6%] in 2008 to 70/94 [74.5%] in 2009) (P<0.01). ICU 
isolates exhibited significantly higher level of resistance to 
imipenem (71.6%) and meropenem (73.4%) compared with 
non-ICU strains (42.6% and 44.6% respectively) (P<0.01). In 
addition, this study revealed that all ICU isolates were (100%) 
resistant to third generation cephalosporins compared with 
non-ICU strains.
Discussion
Within a few decades ago A. baumannii rapidly developed 
resistance to a wide variety of antibiotics that emerged in 
many parts of the world, mostly by acquisition of gene clus-
ters carried by plasmids, transposons, integrons, and resis-
tance islands within the genome 12-17. This phenomenon led 
to the emergence of increasingly multidrug resistance in this 
species 18. To date, some strains of A. baumannii have be-
come resistant to almost all currently available antibacterial 
agents, including carbapenems19-20. In the present study, the 
overall proportion of A. baumannii isolates among all clini-
cal isolates has increased slightly throughout the study from 
3.5% to 4.2%. A. baumannii was the fifth most frequently 
isolated bloodstream microorganism obtained from patients 
in BICU preceded by Staphylococci, Pseudomonas, Klebsiella 
and Candida.
Carbapenem remained the antimicrobial most active anti-
biotic against A. baumannii isolates compared with other 
antibiotics, and there was striking variation during the two 
years of the study, there was significant increase in resis-
tance from 50.6% to 71.3% to imipenem, while meropenem 
showed significantly increased level of resistance from 50.6% 
to 74.5%. Lower rates of resistance was demonstrated in 
some parts of the world such as Taiwan, the carbapenem 
resistance of the Acinetobacter species was 10% 21, (3.2%) 
was reported in Japan 22 and in Saudi Arabia (3.0%) 23. Re-
gional variation in imipenem resistance was also noted when 
North America (4.5% of isolates) and Latin America (11% 
of isolates) were compared 24. Antimicrobial susceptibility 
of 490 A. baumannii strains collected in 37 centres in 11 
European countries from 1997 to 2000, imipenem and me-
ropenem were the most active agents with resistance rates 
of 16% and 18% respectively. Turkey showed the highest 
resistance rates for almost all of the tested antimicrobials, 
followed by Italy and the UK 25. The most recent data for 
2006 from 40 centres in 12 European countries participating 
in the monitory program revealed a considerable increase 
in resistance rates for meropenem (43.4%) and imipenem 
(42.5%) 26 In another study, rate of resistance to imipenem 
has increased from 0% to 42% during the study period 27. In 
Greece, the proportion of imipenem-resistant A. baumannii 
isolates from patients hospitalised between 1996 and 2007 
in tertiary care hospitals in several regions of the country rose 
from 0% to 85.1% (ICUs), 60.4% (medical wards) and 59% 
(surgical wards). Meanwhile, bloodstream isolates from the 
same dataset exhibited even higher resistance rate 28. The 
latest results were relatively similar to our rates of resistance.
ICU isolates exhibited significantly higher level of resistance to 
imipenem (71.6%) and meropenem (73.4%) compared with 
non-ICU strains (42.6% and 44.6% respectively). A. bauman-
nii  and could disseminate in the ICU, probably after con-
tamination of the hospital environment and by nosocomial 
transmission 8, 14, 29-32.A high resistance rate to imipenem 
and meropenem in Acinetobacter  spp. isolates may lead to 
extensive use of polymyxins. Our results was lower than a 
report from the ICUs in Turkey that revealed resistance rates 
of 80.3% and 71.2% for imipenem and meropenem, respec-
tively 33. In a recent report from a single ICU in Bulgaria 
found that carbapenem-resistance was 75% 34 while in a 
UK, a retrospective study on 399 Acinetobacter bacteraemias 
over an eight-year period identified a tremendous increase 
in carbapenem resistance from 0% in 1998 to 55% in 2006 
35. While in Spain, the rate of resistance to imipenem in Aci-
netobacter species is 43% 36. Recently 58% of A. baumannii 
were resistant to imipenem 37.
An outbreak of carbapenem-resistant A. baumannii was de-
scribed in a burn unit of a Norwegian hospital from a trans-
ferred Spanish patient who was identified as the source 38. A 
similar outbreaks were also described in Belgium, UK and US 
39-40. Peleg et al. demonstrated the emergence of carbapen-
em resistance among Australian A. baumannii isolates, it was 
significantly linked to an increased used of meropenem 41. 
Similarly in Taiwan, Ye et al found that the only independent 
risk factor for appearance of imipenem-resistant isolates in 
patients formerly with imipenem-sensitive isolates is the use 
of carbapenem 17. In conclusion, due to the high possibility 
of transmission of the antibiotic resistance through a variety 
of transmissible elements include plasmid and presence of 
many asymptomatic colonizers has raised the importance of 
active surveillance to identify potential colonizers and reser-
voirs of the microorganism combined with implementation 
of infection control measures, including strict hand hygiene, 
appear to be effective in controlling such outbreaks of multi-
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drug resistant bacteria in clinics and hospitals. Furthermore, 
such measures may reduce infection, mortality rates, length 
of hospitalization and associated costs.
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